Manufacturability and the Winners in Advanced Therapies
Are developers still underestimating the engineering sophistication required to scale advanced therapies in the real world? Alan Boyd discusses.
False
Advertisement
Related Content
Cell & Gene
Don’t Forget CDx Developers
November 7, 2014
0 min read
Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.
Cell & Gene
Bioprocessing
Biopharma
The Next Decade of Cell and Gene Therapies
April 2, 2025
5 min read
Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.
Regulation & Standards
Business & Trends
Cell & Gene
Peter Marks Resigns from FDA
April 1, 2025
3 min read
Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”
Business & Trends
Regulation & Standards
Cell & Gene
The Trump Effect on Cell and Gene: Science versus Shockwaves
April 1, 2025
9 min read
Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.